Commissioner McClellan Visits Mass Bio: Phase IV, Orphan Drugs On Agenda
Executive Summary
Phase IV commitments should be discussed earlier in the review process to improve the cost-effectiveness of drug development, the Massachusetts Biotechnology Council told FDA Commissioner McClellan
You may also be interested in...
Phase IV Discussions Should Begin Earlier In Review Process, Wyeth Says
Wyeth wants FDA to direct reviewers to initiate Phase IV discussions with sponsors several weeks before a user fee action date
Phase IV Discussions Should Begin Earlier In Review Process, Wyeth Says
Wyeth wants FDA to direct reviewers to initiate Phase IV discussions with sponsors several weeks before a user fee action date
Genzyme Revises Fabrazyme Phase IV Proposal In Bid For April Approval
Genzyme's proposal for completing its Phase IV Fabrazyme study is the kind of innovative drug development proposal that FDA Commissioner McClellan is encouraging, Genzyme CEO Henri Termeer suggested during a March 5 conference call